Company Filing History:
1 out of 1,744 
1 out of 60 
1 out of 319 
Years Active: 2021
Title: Gilles Wainrib: Innovator in Predictive Medicine
Introduction
Gilles Wainrib is a notable inventor based in Paris, France. He has made significant contributions to the field of predictive medicine, particularly in the treatment of acute severe colitis. His innovative approach has the potential to transform how treatment responses are predicted in patients suffering from this condition.
Latest Patents
Wainrib holds a patent for "Methods for predicting acute severe colitis treatment response." This invention addresses the lack of biomarkers for drug response in patients with acute severe ulcerative colitis. The patent outlines a prediction tool that utilizes the expression levels of specific microRNAs to accurately classify patients as responders or non-responders to various treatments. The prediction accuracy of this tool is an impressive 96.6%.
Career Highlights
Throughout his career, Wainrib has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université de Paris. His research has focused on identifying putative mRNA targets from patient biopsies, leading to the development of algorithms that classify treatment responses.
Collaborations
Wainrib has collaborated with notable colleagues, including Eric Ogier-Denis and Xavier Treton. Their combined expertise has contributed to advancements in understanding treatment responses in acute severe colitis.
Conclusion
Gilles Wainrib's work in predictive medicine exemplifies the impact of innovative thinking in healthcare. His patent for predicting treatment responses in acute severe colitis represents a significant advancement in the field. The potential applications of his research could lead to improved patient outcomes and more personalized treatment strategies.